The cost-effectiveness of long-term post-treatment peer recovery support services in the United States

被引:0
|
作者
de Martell, Sierra Castedo [1 ,2 ]
Moore, Margaret Brannon [2 ]
Wang, Hannah [2 ]
Steiker, Lori Holleran
Wilkerson, J. Michael [2 ]
Ranjit, Nalini [2 ]
Mccurdy, Sheryl A. [2 ]
Brown, H. Shelton [2 ]
机构
[1] Lighthouse Inst, Chestnut Hlth Syst, Bloomington, IL USA
[2] Univ Texas Hlth Sci Ctr Houston, Sch Publ Hlth, Houston, TX USA
基金
美国国家卫生研究院;
关键词
Peer recovery support services; cost-effectiveness analysis; cost-effectiveness calculator; recovery community organizations; recovery community centers; peer coaching; SUBSTANCE-ABUSE TREATMENT; HEALTH;
D O I
10.1080/00952990.2024.2406251
中图分类号
B849 [应用心理学];
学科分类号
040203 ;
摘要
Background: Peer recovery support services (PRSS) have been widely adopted across a variety of settings, but little is known about their economic impact.Objectives: To conduct a cost-effectiveness analysis of long-term, PRSS delivered after specialty substance use disorder (SUD) treatment (post-treatment), and to describe the development of a free, web-based cost-effectiveness calculator based on this analysis.Methods: Using publicly available data from a variety of sources, post-treatment PRSS were compared to specialty SUD treatment from the societal (broad perspective including costs like participant time) and health systems perspectives (only costs borne by health system), and in terms of quality-adjusted life years (QALYs) added and people in recovery. Whenever possible, 2019 data were used to avoid the impacts of COVID-19. Standard willingness-to-pay thresholds and additional treatment episode cost ($17,203.74) were used. One-way and probabilistic sensitivity analyses were conducted. Two recovery community organizations (RCOs) were involved in model refinement and calculator development in 2022.Results: Post-treatment PRSS were cost-effective to all thresholds and perspectives: $5,898.60 per QALY and $10,562.08 per person in recovery from the health system perspective, and $3,421.58 per QALY and $6,126.72 per person in recovery from the societal perspective, and post-treatment PRSS remained cost-effective across a variety of conditions in the sensitivity analyses. A cost-effectiveness calculator was developed from the analysis and is available at https://go.uth.edu/cea.Conclusions: In light of finding PRSS cost-effective, the expansion of PRSS across the US should continue, and may be aided by using the cost-effectiveness calculator to estimate tailored results for a specific program.
引用
收藏
页数:11
相关论文
共 50 条
  • [41] Long-term Clinical Outcomes and Cost-Effectiveness of Obeticholic Acid for Treatment of Nonalcoholic Steatohepatitis
    Chhatwal, Jagpreet
    Samur, Sumeyye
    Klebanoff, Matthew
    Corey, Kathleen E.
    Banken, Reiner
    Chapman, Richard H.
    Ollendorf, Daniel A.
    Hur, Chin
    HEPATOLOGY, 2016, 64 : 53A - 54A
  • [42] Cost-Effectiveness of long-term tolvaptan administration for chronic heart failure treatment in Japan
    Nakao, Yasuhisa
    Kawakami, Hiroshi
    Saito, Makoto
    Inoue, Katsuji
    Ikeda, Shuntaro
    Yamaguchi, Osamu
    JOURNAL OF CARDIOLOGY, 2022, 79 (03) : 408 - 416
  • [43] A COST-EFFECTIVENESS ANALYSIS OF ALTERNATIVE APPROACHES FOR LONG-TERM TREATMENT OF PROXIMAL VENOUS THROMBOSIS
    HULL, RD
    RASKOB, GE
    HIRSH, J
    SACKETT, DL
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1984, 252 (02): : 235 - 239
  • [44] An analytical model to predict the cost-effectiveness of long-term eszopiclone for the treatment of primary insomnia
    Snedecor, S. L.
    Botteman, M. F.
    Schaefer, K.
    Barry, N.
    Rubens, R.
    Pickard, A. S.
    VALUE IN HEALTH, 2007, 10 (06) : A381 - A382
  • [45] Long-term cost-effectiveness of screening strategies for hearing loss
    Liu, Chuan-Fen
    Collins, Margaret P.
    Souza, Pamela E.
    Yueh, Bevan
    JOURNAL OF REHABILITATION RESEARCH AND DEVELOPMENT, 2011, 48 (03): : 235 - 243
  • [46] Long-term cost-effectiveness of weight management in primary care
    Trueman, P.
    Haynes, S. M.
    Lyons, G. Felicity
    McCombie, E. Louise
    McQuigg, M. S. A.
    Mongia, S.
    Noble, P. A.
    Quinn, M. F.
    Ross, H. M.
    Thompson, F.
    Broom, J. I.
    Laws, R. A.
    Reckless, J. P. D.
    Kumar, S.
    Lean, M. E. J.
    Frost, G. S.
    Finer, N.
    Haslam, D. W.
    Morrison, D.
    Sloan, B.
    INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2010, 64 (06) : 775 - 783
  • [47] LONG-TERM COST-EFFECTIVENESS OF EUROFIT VERSUS WAITING LIST
    Finch, A. P.
    Wyke, S.
    Kolovos, S.
    van der Ploeg, H.
    van Nassau, F.
    Bosmans, J. E.
    VALUE IN HEALTH, 2018, 21 : S453 - S453
  • [48] Tuberculosis screening for long-term care: a cost-effectiveness analysis
    Verma, G.
    Chuck, A. W.
    Jacobs, P.
    INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE, 2013, 17 (09) : 1170 - 1177
  • [49] COST-EFFECTIVENESS OF COMPONENTS OF COMMUNITY BASED LONG-TERM CARE
    FAVOR, F
    SKELLIE, FA
    GERONTOLOGIST, 1982, 22 : 133 - 133
  • [50] LONG-TERM COST-EFFECTIVENESS OF VALBENAZINE AND DEUTETRABENAZINE FOR TARDIVE DYSKINESIA
    Harrigan, K.
    Walton, S. M.
    Huang, S. P.
    Kumar, V. M.
    Chapman, R. H.
    Atlas, S. J.
    Agboola, F. O.
    Ollendorf, D. A.
    Touchette, D. R.
    VALUE IN HEALTH, 2018, 21 : S184 - S184